["{\"step_by_step_thinking\": \"The question is about the approved dose of misoprostol in emergent management of postpaum hemorrhage. The given documents are related to various topics such as topical use of Boutycin, ceporexin, antifibrinolytic therapy, and control of acute gingival hemorrhage. Since there is no mention of misoprostol or postpaum hemorrhage in the provided documents, we need to look for information from outside sources. Unfortunately, I do not have any additional information beyond these documents. Therefore, based on the available information, I cannot determine a specific approved dose of misoprostol.\", \"answer_choice\": null}"]